Table 1.
Baseline Demographics of Veterans with Inflammatory Disease Comparing Patients Exposed or Not Exposed to TNFi
| Variable | TNFi exposed (n = 36) | TNFi naïve (n = 72) | P-value |
|---|---|---|---|
| Sex | 1.00 | ||
| Male | 35 (97) | 69 (96) | |
| Female | 1 (3) | 3 (4) | |
| Ethnicity | |||
| Caucasian | 34 (94) | 53 (74) | 0.01a |
| African American | 1 (3) | 16 (22) | 0.01a |
| Hispanic | 1 (3) | 2 (3) | 1.00 |
| Native American | 0 | 1 (1) | 1.00 |
| Charlson Comorbidity Index | 2.5 ± 1.7 | 2.1 ± 1.9 | 0.19 |
| Smoking status | |||
| Never | 7 (19) | 6 (8) | 0.12 |
| Former | 18 (50) | 31 (43) | 0.54 |
| Active | 11 (31) | 35 (49) | 0.10 |
| Inflammatory disease type | |||
| IBD only | |||
| CD | 1 (3) | 2 (3) | 1.00 |
| UC | 2 (6) | 4 (6) | 1.00 |
| Rheumatoid arthritis only | 22 (61) | 48 (67) | 0.67 |
| Psoriasis only | 3 (8) | 10 (13) | 0.54 |
| Spondyloarthropathy only | |||
| Ankylosing spondylitis only | 2 (6) | 2 (3) | 0.60 |
| IBD+spondyloarthropathy | 1 (3) | 0 | 0.33 |
| Psoriasis+psoriatic arthritis | 5 (14) | 6 (8) | 0.50 |
| Age at inflammatory disease diagnosis (yr) | 46.8 ± 12.8 | 52.7 ± 15.0 | 0.02a |
| Inflammatory disease duration (yr) | 22.3 ± 11.0 | 19.1 ± 14.5 | 0.04a |
| Inflammatory disease medication profile at cancer diagnosis | |||
| Concomitant medications | |||
| Oral steroids | 4 (11) | 11 (15) | 0.77 |
| Topical steroids | 14 (39) | 20 (28) | 0.28 |
| 5-Aminosalicylates | 3 (8) | 13 (18) | 0.25 |
| Immunomodulators (thiopurines, methotrexate) | 16 (44) | 25 (35) | 0.40 |
| TNFi | 29 (81) | 0 | - |
| Disease-modifying antirheumatic drugs | 7 (19) | 15 (21) | 1.00 |
| Psoriatic therapy | 5 (14) | 5 (7) | 0.30 |
Values are presented as number (%) or mean±SD.
a
Statistically significant, P<0.05.
TNFi, TNF inhibitors.